12/02/18 Long Term Follow-Up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma, Poster #2892. View the Poster
11/28/18 Intratumoral G100, a TLR4 agonist, induces anti-tumor immune responses and tumor regression in patients with Merkel cell carcinoma. Clinical Cancer Research. November 2018.
11/09/18 Higher Dose Single-Agent Intratumoral G100 (A TLR4 Agonist) Results In Increased Biomarker Activity And Improved Clinical Outcomes In Patients With Follicular Lymphoma. Society for Immunotherapy of Cancer 2018 Annual Meeting. Poster #P327. View Poster
10/22/18 Immune Response, Safety, and Survival Impact from CMB305 in NY-ESO-1+ Recurrent Soft Tissue Sarcomas (C131 Study). Abstract 2951. View Poster
06/23/18 Toll-like receptor 4 expression and functional signaling in human and murine B-cell lymphomas is strongly associated with response to treatment with the synthetic TLR4 agonist G100. AACR International Meeting Advances in Malignant Lymphoma. Abstract #158. View Poster.
04/18/18 Component-specific qPCR assays for characterization and identity testing of multigenome ZVex®, a dendritic cell-targeting lentiviral vector platform. American Association for Cancer Research (AACR) 2018 Annual Meeting. Abstract #5919. View poster.
01/25/18 Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. Abstract #71. View Poster.
01/23/18 Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial. npj Vaccines. January 2018. View Publication.
01/12/18 TLR4 Agonist Glucopyranosyl Lipid A (GLA) Induces T-regulatory Cells and Suppresses Th2 Cytokines in PBMC from Cashew-Allergic Donors. Mechanisms, Prevention of, and Emerging Therapies for Food Allergy Conference 2017. View Poster.
12/10/17 Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/2 Study Examining G100 Alone and in Combination with Pembrolizumab. 59th American Society of Hematology (ASH) Annual meeting. Abstract # 2771. View Poster.
